Next Article in Journal
Maternal Prenatal Inflammation Increases Brain Damage Susceptibility of Lipopolysaccharide in Adult Rat Offspring via COX-2/PGD-2/DPs Pathway Activation
Next Article in Special Issue
Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels
Previous Article in Journal
Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
Previous Article in Special Issue
Agmatine Mitigates Inflammation-Related Oxidative Stress in BV-2 Cells by Inducing a Pre-Adaptive Response
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 11
10.3390/ijms23116143
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target

Int. J. Mol. Sci. 2022, 23(11), 6143; https://doi.org/10.3390/ijms23116143
by Irene L. Gutiérrez 1, Cinzia Dello Russo 2,3, Fabiana Novellino 1,4, Javier R. Caso 1, Borja García-Bueno 1, Juan C. Leza 1 and José L. M. Madrigal 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(11), 6143; https://doi.org/10.3390/ijms23116143
Submission received: 30 April 2022 / Revised: 27 May 2022 / Accepted: 28 May 2022 / Published: 30 May 2022
(This article belongs to the Special Issue Cell Death, Inflammation and Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Cytoprotective Molecules 2.0)

Round 1

Reviewer 1 Report

This review summarizes the relevant literature describing the alterations of the noradrenergic system in Alzheimer´s disease and experimental studies linking noradrenaline function with alterations affecting the behavior and viability of different nervous cells.

Combination of the multiple studies indicate that the maintenance of adequate noradrenaline levels in the central nervous system is critical endogenous defense system that help preventing Alzheimer´s disease.

 

The authors cold try to improve their text and to add a scheme summarizing the multiple mechanisms referred in the manuscript and how they are linked each other. A comment on pre-symptomatic stages such as Mild Cognitive Impairment and noradrenaline should also be included.

A graphical abstract at the beginning might help reader to navigate through this text

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript entitled “Noradrenaline in Alzheimer´s disease: a new potential therapeutic target” summarizes some of the most relevant data describing the alterations of the noradrenergic system typically occurring in Alzheimer´s disease, as well as experimental studies in which noradrenaline concentration was modified to analyze further how these alterations affect the behavior and viability of different nerve cells. The combination of the various studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer´s disease.  The review is informative and well written. The only recommendation is to thoroughly check the spelling and grammar to maintain uniformity (font and size) throughout the manuscript, including the schemes and figures.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop